Last reviewed · How we verify
AllerT low dose
AllerT is an allergen immunotherapy designed to induce immune tolerance to allergens through low-dose, modified allergen exposure.
AllerT is an allergen immunotherapy designed to induce immune tolerance to allergens through low-dose, modified allergen exposure. Used for Allergic rhinitis and/or allergic asthma (in development).
At a glance
| Generic name | AllerT low dose |
|---|---|
| Also known as | AllerT 25-50 micrograms |
| Sponsor | Anergis |
| Drug class | Allergen immunotherapy |
| Modality | Small molecule |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 2 |
Mechanism of action
AllerT works by presenting allergens in a form that promotes regulatory T cell (Treg) development and immune tolerance rather than allergic sensitization. The low-dose formulation is intended to shift the immune response from Th2-mediated allergic inflammation toward Th1/Treg-mediated tolerance, reducing allergic symptoms and potentially providing long-term desensitization.
Approved indications
- Allergic rhinitis and/or allergic asthma (in development)
Common side effects
- Local injection site reactions
- Systemic allergic reactions
- Pruritus
Key clinical trials
- Efficacy Study of a Preseasonal Treatment With AllerT in Subjects With Birch Pollen Allergy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AllerT low dose CI brief — competitive landscape report
- AllerT low dose updates RSS · CI watch RSS
- Anergis portfolio CI